Our findings showed that HDAC inhibitors E2F5 and BCL2 are the therapeutic candidates for gastric carcinomas, which agrees with the hypothesis of HDAC being overexpressed in gastric cancer cell lines. Here, E2F5 is linked to gastric carcinoma.